Edwards Lifesciences - EW Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $125.50
  • Forecasted Upside: 48.45 %
  • Number of Analysts: 20
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 17 Buy Ratings
  • 0 Strong Buy Ratings
$84.54
▲ +1.91 (2.31%)

This chart shows the closing price for EW by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Edwards Lifesciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EW and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EW

Analyst Price Target is $125.50
▲ +48.45% Upside Potential
This price target is based on 20 analysts offering 12 month price targets for Edwards Lifesciences in the last 3 months. The average price target is $125.50, with a high forecast of $144.00 and a low forecast of $106.00. The average price target represents a 48.45% upside from the last price of $84.54.

This chart shows the closing price for EW for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 20 investment analysts is to buy stock in Edwards Lifesciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 15 buy ratings
  • 3 hold ratings
  • 0 sell ratings
4/10/2021
  • 0 strong buy ratings
  • 13 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/9/2021
  • 0 strong buy ratings
  • 13 buy ratings
  • 4 hold ratings
  • 0 sell ratings
10/7/2021
  • 0 strong buy ratings
  • 16 buy ratings
  • 3 hold ratings
  • 0 sell ratings
1/5/2022
  • 0 strong buy ratings
  • 18 buy ratings
  • 4 hold ratings
  • 0 sell ratings
4/5/2022
  • 0 strong buy ratings
  • 19 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/4/2022
  • 0 strong buy ratings
  • 17 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/2/2022
  • 0 strong buy ratings
  • 17 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/2/2022

Latest Recommendations

  • 0 strong buy ratings
  • 17 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/22/2022Truist FinancialLower TargetBuy$117.00 ➝ $112.00Low
7/29/2022Canaccord Genuity GroupDowngradeBuy ➝ Hold$115.00 ➝ $106.00Low
7/29/2022Canaccord Genuity GroupDowngradeBuy ➝ Hold$115.00 ➝ $106.00Low
7/20/2022Truist FinancialLower TargetBuy$140.00 ➝ $120.00Low
7/18/2022Stifel NicolausLower Target$128.00 ➝ $115.00Low
7/15/2022Morgan StanleyLower TargetOverweight$136.00 ➝ $119.00Low
7/11/2022CowenLower Target$140.00 ➝ $125.00N/A
7/11/2022CowenLower Target$140.00 ➝ $125.00N/A
5/17/2022CitigroupLower TargetBuy$134.00 ➝ $115.00N/A
4/27/2022Canaccord Genuity GroupLower Target$152.00 ➝ $137.00High
4/27/2022CitigroupLower Target$138.00 ➝ $134.00High
4/26/2022William BlairReiterated RatingOutperformLow
4/12/2022Truist FinancialInitiated CoverageBuy$145.00Low
4/5/2022Wolfe ResearchInitiated CoverageOutperform$134.00Low
3/16/2022Sanford C. BernsteinUpgradeMarket Perform ➝ Outperform$132.00 ➝ $135.00Low
3/1/2022Bank of AmericaInitiated CoverageNeutral ➝ NeutralLow
2/2/2022UBS GroupUpgradeNeutral ➝ Buy$121.00 ➝ $126.00Low
1/27/2022Evercore ISILower TargetOutperform$130.00 ➝ $122.00High
1/27/2022UBS GroupLower TargetNeutral$125.00 ➝ $121.00High
1/27/2022CitigroupLower TargetBuy$142.00 ➝ $138.00High
1/27/2022Stifel NicolausLower TargetBuy$132.00 ➝ $120.00High
1/27/2022Morgan StanleyLower TargetOverweight$148.00 ➝ $136.00High
1/27/2022Raymond JamesLower TargetOutperform$134.00 ➝ $126.00High
1/27/2022Piper SandlerLower Target$133.00 ➝ $125.00High
1/21/2022SVB LeerinkLower TargetOutperform$135.00 ➝ $132.00High
1/7/2022Credit Suisse GroupBoost TargetOutperform$131.00 ➝ $144.00Low
1/7/2022Morgan StanleyBoost TargetOverweight$144.00 ➝ $148.00Medium
12/17/2021JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$114.00 ➝ $140.00High
12/15/2021CitigroupUpgradeNeutral ➝ Buy$120.00 ➝ $142.00Medium
12/10/2021Raymond JamesBoost TargetOutperform ➝ Outperform$127.00 ➝ $134.00Low
12/9/2021Royal Bank of CanadaInitiated CoverageOutperform$142.00Low
12/9/2021Morgan StanleyBoost TargetOverweight$135.00 ➝ $144.00Medium
12/9/2021SVB LeerinkBoost TargetOutperform$130.00 ➝ $135.00Low
12/8/2021Piper SandlerBoost TargetOverweight ➝ Overweight$123.00 ➝ $133.00Low
12/6/2021Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$126.00High
10/29/2021Jefferies Financial GroupBoost TargetBuy$130.00 ➝ $135.00High
10/28/2021Credit Suisse GroupBoost TargetOutperform$126.00 ➝ $130.00High
10/28/2021Wells Fargo & CompanyBoost TargetEqual Weight$115.00 ➝ $126.00High
10/28/2021Raymond JamesBoost TargetOutperform$122.00 ➝ $127.00High
10/28/2021CitigroupBoost TargetNeutral$113.00 ➝ $120.00High
8/3/2021The Goldman Sachs GroupBoost TargetNeutral$93.00 ➝ $105.00Low
8/2/2021Raymond JamesBoost TargetOutperform$101.00 ➝ $122.00Low
7/30/2021Credit Suisse GroupBoost TargetOutperform$112.00 ➝ $126.00High
7/30/2021Morgan StanleyBoost TargetOverweight$108.00 ➝ $135.00High
7/30/2021OppenheimerBoost TargetOutperform$97.00 ➝ $120.00High
7/30/2021Stifel NicolausBoost TargetBuy$103.00 ➝ $120.00High
7/30/2021UBS GroupBoost TargetNeutral$98.00 ➝ $115.00High
7/30/2021SVB LeerinkBoost TargetOutperform$125.00 ➝ $130.00Medium
7/30/2021Jefferies Financial GroupBoost TargetBuy$110.00 ➝ $130.00High
7/30/2021Wells Fargo & CompanyBoost TargetEqual Weight$93.00 ➝ $115.00High
7/30/2021Deutsche Bank AktiengesellschaftBoost TargetHold$84.00 ➝ $113.00High
7/27/2021Piper SandlerBoost TargetOverweight$105.00 ➝ $120.00Low
7/23/2021CowenBoost TargetOutperform$100.00 ➝ $125.00Low
7/20/2021SVB LeerinkBoost TargetOutperform$106.00 ➝ $125.00Low
5/24/2021BarclaysInitiated CoverageOverweight$110.00Low
4/21/2021Morgan StanleyBoost TargetOverweight$99.00 ➝ $108.00High
4/21/2021Raymond JamesBoost TargetOutperform$96.00 ➝ $101.00High
4/21/2021Wells Fargo & CompanyBoost TargetEqual Weight$87.00 ➝ $93.00High
4/21/2021Piper SandlerBoost TargetOverweight$97.00 ➝ $105.00High
4/15/2021Atlantic SecuritiesInitiated CoverageNeutral$85.00Low
4/5/2021Evercore ISIUpgradeIn-Line ➝ OutperformMedium
12/16/2020Smith Barney CitigroupDowngradeBuy ➝ NeutralLow
12/14/2020Morgan StanleyBoost TargetOverweight$88.00 ➝ $99.00Medium
12/11/2020Raymond JamesBoost TargetOutperform$90.00 ➝ $96.00Low
12/11/2020Piper SandlerBoost TargetOverweight$93.00 ➝ $98.00High
12/11/2020SVB LeerinkBoost TargetOutperform$100.00 ➝ $106.00High
12/7/2020Credit Suisse GroupBoost Target$97.00 ➝ $111.00Medium
11/18/2020Wells Fargo & CompanyBoost TargetEqual Weight$84.00 ➝ $87.00Low
10/27/2020Jefferies Financial GroupBoost TargetBuy$95.00 ➝ $105.00Medium
10/22/2020Credit Suisse GroupBoost TargetOutperform$92.00 ➝ $97.00High
10/22/2020Raymond JamesBoost TargetOutperform$88.00 ➝ $90.00High
10/19/2020CowenBoost TargetOutperform$85.00 ➝ $100.00Medium
10/14/2020Piper SandlerBoost TargetOverweight$91.00 ➝ $93.00Low
10/12/2020SVB LeerinkBoost TargetOutperform$95.00 ➝ $100.00Low
9/11/2020Wolfe ResearchInitiated CoverageUnderperformLow
7/24/2020Stifel NicolausBoost TargetBuy$85.00 ➝ $90.00Low
7/24/2020Jefferies Financial GroupBoost TargetBuy$87.00 ➝ $95.00Low
7/24/2020Credit Suisse GroupBoost TargetOutperform$88.00 ➝ $92.00High
7/24/2020Morgan StanleyBoost TargetOverweight$83.00 ➝ $88.00High
7/24/2020SVB LeerinkBoost TargetOutperform$90.00 ➝ $95.00High
7/24/2020Raymond JamesBoost TargetOutperform$83.00 ➝ $88.00High
7/24/2020Piper SandlerBoost TargetPositive ➝ Overweight$88.00 ➝ $91.00High
7/13/2020OppenheimerInitiated CoverageBuy$93.00High
6/29/2020Morgan StanleyLower TargetOverweight$83.33 ➝ $83.00Low
6/2/2020Credit Suisse GroupLower TargetOutperform$88.00High
6/1/2020Morgan StanleyLower TargetOverweight$83.33 ➝ $83.00N/A
4/28/2020Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$83.33 ➝ $76.67High
4/27/2020BarclaysReiterated RatingUnderweight$55.00 ➝ $51.67High
4/24/2020CfraBoost TargetBuy$67.00 ➝ $77.00Low
4/24/2020Raymond JamesBoost TargetOutperform$76.67 ➝ $83.33Low
4/24/2020Stifel NicolausBoost TargetBuy$76.67 ➝ $85.00Low
4/24/2020Piper SandlerLower TargetOverweight$90.00 ➝ $88.33Low
4/24/2020Morgan StanleyBoost TargetOverweight$80.33 ➝ $83.33High
4/24/2020Credit Suisse GroupBoost TargetOutperform$86.67 ➝ $87.33High
4/24/2020Wells Fargo & CompanyBoost TargetOverweight$71.67 ➝ $83.33High
4/24/2020CitigroupBoost TargetBuy$80.00 ➝ $85.00High
4/23/2020BTIG ResearchReiterated RatingHoldHigh
4/22/2020Deutsche Bank AktiengesellschaftLower TargetHold$81.67 ➝ $75.00Low
4/20/2020CowenLower TargetTop Pick ➝ Outperform$91.67 ➝ $83.33Medium
4/19/2020SVB LeerinkDowngradeOutperform ➝ Market PerformMedium
4/17/2020SVB LeerinkUpgradeMarket Perform ➝ Outperform$90.00High
4/9/2020Raymond JamesLower TargetOutperform$87.67 ➝ $76.67High
4/6/2020Wells Fargo & CompanyLower TargetOverweight$90.67 ➝ $71.67Low
3/27/2020Morgan StanleyLower TargetOverweight$90.00 ➝ $80.33Low
3/27/2020CitigroupLower TargetBuy$84.00 ➝ $80.00Low
3/13/2020CfraUpgradeSell ➝ Hold$69.00 ➝ $67.00High
3/6/2020Credit Suisse GroupLower TargetOutperform$92.67 ➝ $89.00Low
3/4/2020CitigroupInitiated CoverageBuy$84.00Low
2/12/2020The Goldman Sachs GroupInitiated CoverageNeutral$84.33Low
2/6/2020BTIG ResearchInitiated CoverageHoldMedium
1/31/2020CfraBoost TargetSell$68.33 ➝ $69.00High
1/31/2020Stifel NicolausBoost TargetBuy$91.67 ➝ $93.33High
1/31/2020Wells Fargo & CompanyBoost TargetOverweight$90.00 ➝ $90.67High
1/31/2020Deutsche Bank AktiengesellschaftBoost TargetHold$78.67 ➝ $81.67High
1/31/2020Credit Suisse GroupBoost TargetOutperform$91.67 ➝ $92.67High
1/31/2020Piper SandlerBoost TargetOverweight$87.33 ➝ $90.00High
1/31/2020UBS GroupBoost TargetNeutral$85.00 ➝ $86.67High
1/9/2020OppenheimerUpgradeMarket Perform ➝ Buy$93.33Medium
1/3/2020Deutsche Bank AktiengesellschaftInitiated CoverageHold$54.67Low
12/17/2019CowenReiterated RatingBuy$91.67Medium
12/9/2019Piper Jaffray CompaniesBoost TargetOverweight$85.00 ➝ $87.33High
12/6/2019UBS GroupBoost TargetNeutral$83.33 ➝ $85.00High
12/6/2019Wells Fargo & CompanyBoost TargetOutperform$87.33 ➝ $90.00High
12/6/2019Credit Suisse GroupBoost TargetOutperform$89.67 ➝ $91.67High
12/6/2019Morgan StanleyBoost TargetOverweight$82.67 ➝ $90.00High
12/6/2019Raymond JamesBoost TargetOutperform$85.00 ➝ $87.67High
12/3/2019Jefferies Financial GroupBoost TargetBuy$85.00 ➝ $95.00Low
10/24/2019Raymond JamesBoost TargetOutperform$83.33 ➝ $85.00High
10/24/2019CowenBoost TargetOutperform ➝ Positive$83.33 ➝ $88.33High
10/24/2019Wells Fargo & CompanyBoost TargetOutperform$83.33 ➝ $87.33High
10/24/2019Piper Jaffray CompaniesBoost TargetOverweight$80.00 ➝ $85.00High
10/22/2019Royal Bank of CanadaBoost TargetBuy ➝ Outperform$72.33 ➝ $83.33Medium
10/16/2019UBS GroupBoost TargetNeutral$68.33 ➝ $76.67Low
10/14/2019Raymond JamesBoost TargetOutperform$77.33 ➝ $83.33Low
10/14/2019Credit Suisse GroupBoost TargetPositive ➝ Outperform$75.33 ➝ $87.00Low
9/23/2019Piper Jaffray CompaniesInitiated CoverageOverweight$80.00 ➝ $80.00Low
9/6/2019Wells Fargo & CompanyBoost TargetOutperform$73.33 ➝ $83.33Low
7/26/2019CitigroupSet TargetSell$53.00Low
7/25/2019BTIG ResearchReiterated RatingHoldLow
7/24/2019BMO Capital MarketsBoost TargetOutperform$68.00 ➝ $74.67Low
7/24/2019JPMorgan Chase & Co.Boost TargetNeutral$63.33 ➝ $75.00Low
7/24/2019Bank of AmericaReiterated RatingBuy ➝ Buy$71.67 ➝ $75.00Low
7/24/2019Wells Fargo & CompanyBoost TargetOutperform$69.00 ➝ $73.33High
7/24/2019Morgan StanleyBoost TargetOverweight$70.00 ➝ $76.00High
7/24/2019Raymond JamesBoost TargetOutperform$66.67 ➝ $77.33High
7/24/2019BarclaysBoost TargetUnderweight$53.33 ➝ $58.33High
7/24/2019Credit Suisse GroupBoost TargetOutperform$73.67 ➝ $75.33High
7/24/2019Jefferies Financial GroupBoost TargetBuy$70.00 ➝ $81.67High
7/16/2019Morgan StanleyBoost TargetOverweight$65.67 ➝ $70.00Medium
4/24/2019Stifel NicolausBoost TargetBuy ➝ Buy$63.33 ➝ $66.67Low
4/24/2019Deutsche Bank AktiengesellschaftBoost TargetHold ➝ Hold$54.67 ➝ $61.33Low
4/24/2019Jefferies Financial GroupBoost TargetBuy$65.00 ➝ $70.00Low
4/24/2019Raymond JamesLower TargetOutperform ➝ Outperform$70.00 ➝ $66.67Low
4/24/2019BTIG ResearchReiterated RatingHoldLow
4/15/2019Credit Suisse GroupBoost TargetOutperform ➝ Outperform$63.00 ➝ $73.67Low
3/27/2019JPMorgan Chase & Co.Boost TargetNeutral$58.33 ➝ $63.33Low
3/25/2019BarclaysBoost TargetUnderweight$50.00 ➝ $53.33Low
3/22/2019BMO Capital MarketsBoost TargetOutperform$68.00Low
3/18/2019Morgan StanleyBoost TargetOverweight ➝ Overweight$60.00 ➝ $65.67High
3/18/2019Wells Fargo & CompanyBoost TargetOutperform$62.67 ➝ $67.33High
3/18/2019Bank of AmericaBoost TargetBuy ➝ Buy$63.33 ➝ $71.67Medium
3/12/2019UBS GroupBoost TargetNeutral ➝ Neutral$58.33 ➝ $60.00Medium
2/25/2019CitigroupBoost TargetSell ➝ Sell$39.67 ➝ $43.33Medium
2/4/2019CowenReiterated RatingBuyMedium
2/3/2019Stifel NicolausReiterated RatingBuy$63.33Medium
1/18/2019Bank of AmericaUpgradeNeutral ➝ Buy$60.00 ➝ $63.33High
1/2/2019Deutsche Bank AktiengesellschaftInitiated CoverageHold ➝ Hold$54.67High
1/2/2019CitigroupBoost TargetSell ➝ Sell$39.33 ➝ $39.67Low
12/17/2018Credit Suisse GroupInitiated CoverageOutperform$62.67Low
12/10/2018CowenSet TargetBuy$63.33Low
12/7/2018Morgan StanleyBoost TargetOverweight ➝ Overweight$52.33 ➝ $60.00Medium
12/6/2018Stifel NicolausReiterated RatingPositiveHigh
12/6/2018Raymond JamesBoost TargetOutperform ➝ Outperform$53.33 ➝ $58.33High
12/6/2018Royal Bank of CanadaBoost TargetOutperform$58.33High
12/6/2018Jefferies Financial GroupBoost TargetPositive ➝ Buy$56.00 ➝ $60.00High
11/30/2018CowenSet TargetBuy$63.33Low
11/27/2018UBS GroupInitiated CoverageNeutral ➝ Neutral$55.00 ➝ $55.00High
10/29/2018CitigroupLower TargetSell ➝ Sell$40.33 ➝ $39.33High
10/24/2018BarclaysSet TargetSell$47.67High
10/15/2018BarclaysInitiated CoverageUnderweight ➝ Underweight$47.67High
10/11/2018Morgan StanleyBoost TargetOverweight$50.00 ➝ $52.33Medium
10/11/2018Northland SecuritiesReiterated RatingHold$40.00Medium
10/2/2018Bank of AmericaDowngradeBuy ➝ NeutralMedium
10/2/2018GuggenheimDowngradeBuy ➝ NeutralHigh
9/28/2018SunTrust BanksBoost TargetBuy$66.67Medium
8/10/2018SunTrust BanksLower TargetBuy$56.67Low
7/31/2018CitigroupBoost TargetSell ➝ Sell$38.33 ➝ $39.33Low
7/27/2018GuggenheimReiterated RatingBuy$56.67Low
7/27/2018Morgan StanleyBoost TargetOverweight ➝ Overweight$46.00 ➝ $50.00Medium
7/27/2018Wells Fargo & CompanyBoost TargetOutperform ➝ Outperform$50.67 ➝ $56.67Medium
7/27/2018JPMorgan Chase & Co.Boost TargetNeutral ➝ Neutral$44.33 ➝ $50.00High
7/27/2018Jefferies Financial GroupReiterated RatingBuy$56.00High
7/27/2018Northland SecuritiesReiterated RatingHold$40.00High
7/10/2018BMO Capital MarketsBoost TargetOutperform$54.00Low
6/27/2018Sanford C. BernsteinInitiated CoverageMarket Perform$55.00High
5/31/2018Raymond JamesInitiated CoverageOutperform$50.67Low
5/23/2018Royal Bank of CanadaBoost TargetOutperform$48.33High
4/25/2018Royal Bank of CanadaReiterated RatingOutperform$46.67Low
4/25/2018Northland SecuritiesDowngradeOutperform ➝ Market PerformHigh
4/10/2018SunTrust BanksReiterated RatingBuy$60.00Medium
3/20/2018CowenReiterated RatingBuy$55.00Low
2/2/2018GuggenheimReiterated RatingBuy$54.00Low
2/2/2018JMP SecuritiesBoost TargetMarket Outperform ➝ Market Outperform$45.00 ➝ $46.67High
2/2/2018Stifel NicolausReiterated RatingBuy$51.67High
2/2/2018BarclaysBoost TargetOverweight ➝ Overweight$45.00 ➝ $51.67High
2/2/2018Morgan StanleyBoost TargetOverweight ➝ Overweight$43.33 ➝ $46.00High
2/1/2018CowenReiterated RatingBuy$50.00High
1/31/2018SunTrust BanksReiterated RatingBuy$50.00Low
1/4/2018BarclaysUpgradeEqual Weight ➝ Overweight$41.67 ➝ $45.00Low
1/3/2018Evercore ISIInitiated CoverageOutperform ➝ Outperform$46.67High
1/2/2018JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralMedium
12/10/2017CowenSet TargetBuy$45.00Low
12/8/2017BMO Capital MarketsReiterated RatingBuy$45.67Low
10/26/2017Deutsche Bank AktiengesellschaftLower TargetHold$40.67 ➝ $38.33N/A
10/26/2017Morgan StanleyLower TargetOverweight$44.33 ➝ $40.00N/A
10/25/2017BarclaysLower TargetEqual Weight$40.00 ➝ $39.33N/A
10/25/2017SunTrust BanksSet TargetBuy$41.33N/A
10/12/2017CowenReiterated RatingBuy$45.00N/A
(Data available from 10/3/2017 forward)

News Sentiment Rating

0.77 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 17 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/7/2022
  • 4 very positive mentions
  • 10 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
4/6/2022
  • 9 very positive mentions
  • 30 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
5/6/2022
  • 0 very positive mentions
  • 22 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/5/2022
  • 7 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/5/2022
  • 3 very positive mentions
  • 24 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
8/4/2022
  • 3 very positive mentions
  • 23 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/3/2022
  • 9 very positive mentions
  • 6 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
10/3/2022

Current Sentiment

  • 9 very positive mentions
  • 6 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Edwards Lifesciences logo
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Read More

Today's Range

Now: $84.54
Low: $83.16
High: $85.77

50 Day Range

MA: $95.29
Low: $82.37
High: $107.29

52 Week Range

Now: $84.54
Low: $81.87
High: $131.73

Volume

41,463 shs

Average Volume

2,691,747 shs

Market Capitalization

$52.41 billion

P/E Ratio

36.60

Dividend Yield

N/A

Beta

1.13

Frequently Asked Questions

What sell-side analysts currently cover shares of Edwards Lifesciences?

The following equities research analysts have issued reports on Edwards Lifesciences in the last twelve months: Bank of America Co., Canaccord Genuity Group Inc., Citigroup Inc., Cowen Inc, Cowen Inc., Credit Suisse Group AG, Evercore ISI, Jefferies Financial Group Inc., JPMorgan Chase & Co., Morgan Stanley, Piper Sandler, Raymond James, Royal Bank of Canada, Sanford C. Bernstein, Stifel Nicolaus, StockNews.com, SVB Leerink LLC, Truist Financial Co., UBS Group AG, Wells Fargo & Company, William Blair, and Wolfe Research.
View the latest analyst ratings for EW.

What is the current price target for Edwards Lifesciences?

20 Wall Street analysts have set twelve-month price targets for Edwards Lifesciences in the last year. Their average twelve-month price target is $125.50, suggesting a possible upside of 48.5%. Credit Suisse Group AG has the highest price target set, predicting EW will reach $144.00 in the next twelve months. Canaccord Genuity Group Inc. has the lowest price target set, forecasting a price of $106.00 for Edwards Lifesciences in the next year.
View the latest price targets for EW.

What is the current consensus analyst rating for Edwards Lifesciences?

Edwards Lifesciences currently has 3 hold ratings and 17 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe EW will outperform the market and that investors should add to their positions of Edwards Lifesciences.
View the latest ratings for EW.

What other companies compete with Edwards Lifesciences?

Other companies that are similar to Edwards Lifesciences include Intuitive Surgical, STERIS, Zimmer Biomet, Align Technology and McKesson. Learn More about companies similar to Edwards Lifesciences.

How do I contact Edwards Lifesciences' investor relations team?

Edwards Lifesciences' physical mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The medical research company's listed phone number is (949) 250-2500 and its investor relations email address is [email protected] The official website for Edwards Lifesciences is www.edwards.com. Learn More about contacing Edwards Lifesciences investor relations.